Literature DB >> 16252234

Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.

Anna M G Pasmooij1, Hendri H Pas, Franciska C L Deviaene, Miranda Nijenhuis, Marcel F Jonkman.   

Abstract

Revertant mosaicism by somatic reversion of inherited mutations has been described for a number of genetic diseases. Several mechanisms can underlie this reversion process, such as gene conversion, crossing-over, true back mutation, and second-site mutation. Here, we report the occurrence of multiple corrections in two unrelated probands with revertant mosaicism of non-Herlitz junctional epidermolysis bullosa, an autosomal recessive genodermatosis due to mutations in the COL17A1 gene. Immunofluorescence microscopy and laser dissection microscopy, followed by DNA and RNA analysis, were performed on skin biopsy specimens. In patient 1, a true back mutation, 3781T-->C, was identified in the specimen from the arm, and a second-site mutation, 4463-1G-->A, which compensated for the frameshift caused by the inherited 4424-5insC mutation, was identified in the 3' splice site of exon 55 in a specimen from the middle finger. Patient 2 showed--besides two distinct gene conversion events in specimens from the arm and hand sites, both of which corrected the 1706delA mutation--a second-site mutation (3782G-->C) in an ankle specimen, which prevented the premature ending of the protein by the 3781C-->T nonsense mutation (R1226X). Thus, both inherited mutations, paternal as well as maternal, reverted at least once by different reversion events in distinct cell clusters in the described patients. The occurrence of multiple correcting mutations within the same patient indicates that in vivo reversion is less unusual than was generally thought. Furthermore, in the male patient, mosaic patterns of type XVII collagen-positive keratinocytes were present in clinically unaffected and affected skin. This latter observation makes it likely that reversion may be overlooked and may happen more often than expected.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16252234      PMCID: PMC1271383          DOI: 10.1086/497344

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  36 in total

1.  Estimate of the mutation rate per nucleotide in humans.

Authors:  M W Nachman; S L Crowell
Journal:  Genetics       Date:  2000-09       Impact factor: 4.562

2.  Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex.

Authors:  Frances J D Smith; Susan M Morley; W H Irwin McLean
Journal:  J Invest Dermatol       Date:  2004-01       Impact factor: 8.551

3.  Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis.

Authors:  R Jorquera; R M Tanguay
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

4.  Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.

Authors:  Y T Bliksrud; E Brodtkorb; P A Andresen; I E T van den Berg; E A Kvittingen
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

5.  Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings.

Authors:  Taizo Wada; Akihiro Konno; Shepherd H Schurman; Elizabeth K Garabedian; Stacie M Anderson; Martha Kirby; David L Nelson; Fabio Candotti
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 6.  In vivo reversion to normal of inherited mutations in humans.

Authors:  R Hirschhorn
Journal:  J Med Genet       Date:  2003-10       Impact factor: 6.318

Review 7.  Natural repair mechanisms in correcting pathogenic mutations in inherited skin disorders.

Authors:  M F Jonkman; M Castellanos Nuijts; A J van Essen
Journal:  Clin Exp Dermatol       Date:  2003-11       Impact factor: 3.470

8.  Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia.

Authors:  Sylvie I Demers; Pierre Russo; Francine Lettre; Robert M Tanguay
Journal:  Hum Pathol       Date:  2003-12       Impact factor: 3.466

9.  Focal activation of a mutant allele defines the role of stem cells in mosaic skin disorders.

Authors:  M J Arin; M A Longley; X J Wang; D R Roop
Journal:  J Cell Biol       Date:  2001-02-05       Impact factor: 10.539

10.  An inducible mouse model for epidermolysis bullosa simplex: implications for gene therapy.

Authors:  T Cao; M A Longley; X J Wang; D R Roop
Journal:  J Cell Biol       Date:  2001-02-05       Impact factor: 10.539

View more
  21 in total

Review 1.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

2.  Epidermolysis bullosa. I. Molecular genetics of the junctional and hemidesmosomal variants.

Authors:  R Varki; S Sadowski; E Pfendner; J Uitto
Journal:  J Med Genet       Date:  2006-02-10       Impact factor: 6.318

3.  Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy.

Authors:  Antoni Gostyński; Sara Llames; Marta García; María J Escamez; Lucía Martinez-Santamaria; Miranda Nijenhuis; Alvaro Meana; Hendri H Pas; Fernando Larcher; Anna M G Pasmooij; Marcel F Jonkman; Marcela Del Rio
Journal:  J Invest Dermatol       Date:  2013-07-24       Impact factor: 8.551

4.  Somatic mosaicism with reversion to normality of a mutated transthyretin allele related to a familial amyloidotic polyneuropathy.

Authors:  Concetta Federico; Ketty Dugo; Francesca Bruno; Anna Maria Longo; Agata Grillo; Salvatore Saccone
Journal:  Hum Genet       Date:  2017-05-15       Impact factor: 4.132

Review 5.  The genetics of human skin disease.

Authors:  Gina M DeStefano; Angela M Christiano
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-01       Impact factor: 6.915

Review 6.  Genetics and epigenetics of the skin meet deep sequence.

Authors:  Jeffrey B Cheng; Raymond J Cho
Journal:  J Invest Dermatol       Date:  2012-01-12       Impact factor: 8.551

7.  Expanding the Mutation Spectrum of Ichthyosis with Confetti.

Authors:  Young H Lim; Keith A Choate
Journal:  J Invest Dermatol       Date:  2016-10       Impact factor: 8.551

8.  Kinetic properties of mutant deoxyguanosine kinase in a case of reversible hepatic mtDNA depletion.

Authors:  Bénédicte Mousson de Camaret; Jan-Willem Taanman; Sylvie Padet; Maïté Chassagne; Martine Mayençon; Pascale Clerc-Renaud; Ginette Mandon; Marie-Thérèse Zabot; Alain Lachaux; Dominique Bozon
Journal:  Biochem J       Date:  2007-03-01       Impact factor: 3.857

9.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  A reversion of an IL2RG mutation in combined immunodeficiency providing competitive advantage to the majority of CD8+ T cells.

Authors:  Taco W Kuijpers; Ester M M van Leeuwen; Barbara H Barendregt; Paul Klarenbeek; Daan J aan de Kerk; Paul A Baars; Machiel H Jansen; Niek de Vries; René A W van Lier; Mirjam van der Burg
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.